{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:42:50Z","timestamp":1791517370595,"version":"4.3.4"},"reference-count":44,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["32003B_185111"],"award-info":[{"award-number":["32003B_185111"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["P500PM_210867"],"award-info":[{"award-number":["P500PM_210867"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016015","name":"Universit\u00e4tsspital Basel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>Lysergic acid diethylamide (LSD) is currently being investigated as a potential treatment for psychiatric and neurological disorders. Different LSD formulations (base or tartrate, oral or intravenous) are being used. Unclear is whether LSD base and tartrate pharmacokinetics are equivalent. Additionally, LSD's absolute oral bioavailability is unknown. Therefore, we tested the bioequivalence of different oral LSD base and tartrate formulations and defined LSD's absolute oral bioavailability at a dose of ~80\u2009\u03bcg freebase equivalent. We used a randomized, double\u2010blind, placebo\u2010controlled, five\u2010period crossover design in 20 healthy participants to investigate an ethanolic drinking solution of LSD base, a watery drinking solution of LSD tartrate, a rapid dissolvable tablet of LSD base, an intravenous formulation of LSD tartrate, and corresponding placebos. We assessed pharmacokinetic parameters and acute subjective, autonomic, and adverse effects up to 24\u2009hours. All oral formulations were bioequivalent, with the ethanolic base solution as a reference. The area under the concentration\u2013time curve from zero to infinity and maximum plasma concentration were within a 90% confidence interval of 80\u2013125%. The absolute bioavailability of oral LSD was 80% and similar for all tested formulations. Overall, the oral formulations showed comparable pharmacokinetic and pharmacodynamic parameters. Intravenous LSD administration produced higher \u201cany drug effect,\u201d \u201cgood drug effect,\u201d and \u201cego dissolution\u201d compared with oral LSD tartrate, more \u201canxiety\u201d compared with all oral formulations, and more \u201cnausea\u201d and \u201cbad drug effect\u201d compared with oral LSD base and tartrate. In conclusion, dosing with LSD base and tartrate can be considered bioequivalent with high and similar oral bioavailability.<\/jats:p>","DOI":"10.1002\/cpt.3726","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T08:24:21Z","timestamp":1748247861000},"page":"735-743","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Absolute Oral Bioavailability and Bioequivalence of <scp>LSD<\/scp> Base and Tartrate in a Double\u2010Blind, Placebo\u2010Controlled, Crossover Study"],"prefix":"10.1002","volume":"118","author":[{"given":"Denis","family":"Arikci","sequence":"first","affiliation":[{"name":"Clinical Pharmacology and Toxicology, Department of Biomedicine University Hospital Basel  Basel Switzerland"},{"name":"Department of Clinical Research University Hospital Basel  Basel Switzerland"},{"name":"Department of Pharmaceutical Sciences University of Basel  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3143-1519","authenticated-orcid":false,"given":"Friederike","family":"Holze","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Toxicology, Department of Biomedicine University Hospital Basel  Basel Switzerland"},{"name":"Department of Clinical Research University Hospital Basel  Basel Switzerland"},{"name":"Department of Pharmaceutical Sciences University of Basel  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9155-1080","authenticated-orcid":false,"given":"Lorenz","family":"Mueller","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Toxicology, Department of Biomedicine University Hospital Basel  Basel Switzerland"},{"name":"Department of Clinical Research University Hospital Basel  Basel Switzerland"},{"name":"Department of Pharmaceutical Sciences University of Basel  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5954-4446","authenticated-orcid":false,"given":"Patrick","family":"Vizeli","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Toxicology, Department of Biomedicine University Hospital Basel  Basel Switzerland"},{"name":"Department of Clinical Research University Hospital Basel  Basel Switzerland"},{"name":"Department of Pharmaceutical Sciences University of Basel  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3069-9732","authenticated-orcid":false,"given":"Deborah","family":"Rudin","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Toxicology, Department of Biomedicine University Hospital Basel  Basel Switzerland"},{"name":"Department of Clinical Research University Hospital Basel  Basel Switzerland"},{"name":"Department of Pharmaceutical Sciences University of Basel  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0874-4875","authenticated-orcid":false,"given":"Dino","family":"Luethi","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Toxicology, Department of Biomedicine University Hospital Basel  Basel Switzerland"},{"name":"Department of Clinical Research University Hospital Basel  Basel Switzerland"},{"name":"Department of Pharmaceutical Sciences University of Basel  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric M.","family":"Hysek","sequence":"additional","affiliation":[{"name":"Apotheke Dr. Hysek AG  Biel\/Bienne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1765-9659","authenticated-orcid":false,"given":"Matthias E.","family":"Liechti","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Toxicology, Department of Biomedicine University Hospital Basel  Basel Switzerland"},{"name":"Department of Clinical Research University Hospital Basel  Basel Switzerland"},{"name":"Department of Pharmaceutical Sciences University of Basel  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"e_1_2_11_1_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2016.05.001"},{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyac075"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-020-00883-6"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2022.08.025"},{"key":"e_1_2_11_5_1","unstructured":"European Monitoring Centre for Drugs and Drug Addiction.European Drug Report2022.Lisbon:European Monitoring Centre for Drugs and Drug Addiction<https:\/\/op.europa.eu\/en\/publication\u2010detail\/\u2010\/publication\/2d48883c\u2010ed1f\u201011ec\u2010a534\u201001aa75ed71a1\/language\u2010en> (2022) Accessed December 5 2022."},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-021-05978-6"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13918"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-018-5119-x"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-019-05417-7"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpsc.2019.12.007"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2019.05.019"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291715002901"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1518377113"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/adb.13143"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01772-4"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyv072"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0513-9"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15887"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2057"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt196455611"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/00223980.1955.9712962"},{"key":"e_1_2_11_22_1","unstructured":"European Medicines Agency.Guideline for the Investigation of Bioequivalence. London: European Medicines Agency. <https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/guideline\u2010investigation\u2010bioequivalence\u2010rev1_en.pdf> (2010) Accessed August 13 2020."},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-019-0569-3"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2014.11.015"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-022-01297-2"},{"key":"e_1_2_11_26_1","volume-title":"Die Eigenschaftsw\u00f6rterliste","author":"Janke W.","year":"1978"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-979351"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012412"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-016-4453-0"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881115609019"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811231199112"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/emj.2009.079905"},{"key":"e_1_2_11_33_1","volume-title":"Die Beschwerden\u2010Liste. M\u00fcnchener Informationssystem","author":"Zerssen D.V.","year":"1976"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01609-0"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01607-2"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2020.10.002"},{"key":"e_1_2_11_37_1","unstructured":"Food and Drug Administration.Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under a guidance for industry(2021)."},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2019.04.013"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-90343-y"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-024-03074-9"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02477-4"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2821"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811231196877"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1994.03950020022002"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.3726","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T05:57:54Z","timestamp":1755237474000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.3726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/cpt.3726"],"URL":"https:\/\/doi.org\/10.1002\/cpt.3726","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"2025-02-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}